$1.81
+0.11 (+6.47%)
Open$1.71
Previous Close$1.70
Day High$1.82
Day Low$1.70
52W High$48.45
52W Low$29.26
Volume—
Avg Volume151.6K
Market Cap114.50M
P/E Ratio27.02
EPS$1.45
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+2,322.7% upside
Current
$1.81
$1.81
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 20.64M | 19.43M | 16.17M |
| Net Income | 4.40M | 4.04M | 2.70M |
| Profit Margin | 21.3% | 20.8% | 16.7% |
| EBITDA | 5.96M | 6.14M | 4.71M |
| Free Cash Flow | 3.87M | 2.37M | 2.40M |
| Rev Growth | +16.0% | +14.5% | +17.0% |
| Debt/Equity | 0.20 | 0.18 | 0.17 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |